Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00

Palvella Therapeutics (NASDAQ:PVLA) had its price target hoisted by Chardan Capital from $60.00 to $73.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

PVLA has been the subject of a number of other reports. Oppenheimer began coverage on Palvella Therapeutics in a report on Tuesday, September 9th. They set an “outperform” rating and a $85.00 price target for the company. Stifel Nicolaus increased their target price on shares of Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. HC Wainwright lifted their price target on shares of Palvella Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial started coverage on shares of Palvella Therapeutics in a report on Monday, July 21st. They issued a “buy” rating and a $56.00 price objective on the stock. Finally, Raymond James Financial set a $54.00 target price on shares of Palvella Therapeutics and gave the company an “outperform” rating in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company. According to MarketBeat.com, Palvella Therapeutics currently has an average rating of “Buy” and an average price target of $67.09.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $59.59 on Friday. The company has a market capitalization of $659.07 million, a P/E ratio of -4.92 and a beta of -0.04. The company has a 50 day simple moving average of $48.78 and a 200-day simple moving average of $32.91. Palvella Therapeutics has a 1 year low of $11.17 and a 1 year high of $63.12.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). As a group, research analysts expect that Palvella Therapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PVLA. Frazier Life Sciences Management L.P. lifted its holdings in Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after buying an additional 32,388 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Palvella Therapeutics during the second quarter worth $104,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at $85,000. Marshall Wace LLP boosted its holdings in Palvella Therapeutics by 61.7% in the second quarter. Marshall Wace LLP now owns 49,077 shares of the company’s stock valued at $1,106,000 after purchasing an additional 18,732 shares during the period. Finally, New York State Common Retirement Fund acquired a new position in Palvella Therapeutics during the 2nd quarter worth $110,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.